'Best days are still ahead' for top opioid addiction treatment Vivitrol, CEO says

But after years of steady growth for its leading drugs — Vivitrol, which treats opioid addiction, and Aristada, which treats schizophrenia — 2018 will be a year of milestones, Alkermes CEO Richard Pops told CNBC on Monday. "I think the best days of Vivitrol are still ahead of it," Pops told "Mad Money" ...